Development portfolio by therapeutic area

Oncology

Phase I

Additional Indications

OPDIVO*
– Solid Tumors

OPDIVO* **+ *YERVOY****
– Solid Tumors

Investigational Compounds

motolimod
– SCCHN

relatlimab*^
– Solid Tumors

Anti-TIM-3^
– Solid Tumors

STING Agonist
– Solid Tumors

AHR Antagonist*
– Solid Tumors

Anti-CTLA-4 NF-Probody
– Solid Tumors

BET Inhibitor (CC-95775)^
– Solid Tumors

Anti-SIRPα
– Solid Tumors

CD3xPSCA*
– Solid Tumors

Anti-IL8^
– Solid Tumors

AR-LDD
– Solid Tumors

Anti-NKG2A
– Solid Tumors

TGFβ Inhibitor
– Solid Tumors

IL-12 Fc
– Solid Tumors

Anti-CCR8
– Solid Tumors

TIGIT Bispecific*
– Solid Tumors

farletuzumab-eribulin ADC*
– Solid Tumors

MAGE A4/8 TCE-Bispecific*
– Solid Tumors

Phase II

Additional Indications

OPDIVO*
– Solid Tumors
– 1L CRC
– Pan Tumor TMB High
– Pediatric

OPDIVO* **+ *YERVOY****
– Solid Tumors
– Metastatic Castration-Resistant Prostate

OPDIVO* **+ CDK4/6 Inhibitor**
– Neoadjuvant ER+/HER2- Breast

OPDIVO* **+ relatlimab***
– Solid Tumors

OPDIVO* **+ linrodostat**
– Solid Tumors

OPDIVO* **+ bempegaldesleukin***
– 1L Bladder#

POMALYST/IMNOVID
– Pediatric Glioblastoma

Investigational Compounds

Anti-CTLA-4 NF^
– Solid Tumors

Anti-CTLA-4 Probody^
– Solid Tumors

Anti-TIGIT^
– Solid Tumors

Anti-Fucosyl GM1
– Solid Tumors

LSD1 Inhibitor
– Extensive Stage SCLC

BET Inhibitor (CC-90010)^
– Solid Tumors

farletuzumab-eribulin ADC*
– Solid Tumors

subcutaneous nivolumab + rHuPH20*
– Solid Tumors

Phase III

Additional Indications

OPDIVO*
– 1L Glioblastoma
– 1L HCC
– 1L Head & Neck
– 1L Head & Neck Locally Advanced
– 1L Esophageal
– High-Risk Non-Muscle Invasive Bladder Cancer
– Adjuvant Gastric
– Adjuvant HCC
– Adjuvant Melanoma
– Adjuvant RCC
– Metastatic Castration-Resistant Prostate
– Neoadjuvant ER+/HER2- Breast
– Neoadjuvant NSCLC
– Peri-adjuvant NSCLC
– Unresectable NSCLC

OPDIVO* **+ *YERVOY****
– 1L Bladder
– 1L Esophageal
– 1L Gastric
– 1L HCC
– Intermediate HCC
– 1L CRC (MSI-High)
– Adjuvant Melanoma
– Adjuvant RCC
– NSCLC EGFR Mutant
– Unresectable NSCLC

OPDIVO* **+ relatlimab***
– 1L Melanoma

OPDIVO* **+ linrodostat**
– Neoadjuvant Muscle Invasive Bladder Cancer

OPDIVO* **+ bempegaldesleukin***
– 1L Melanoma
– Adjuvant Melanoma#
– Muscle Invasive Bladder Cancer
– 1L RCC#

OPDIVO* **+ *YERVOY**** **+ cabozantinib***
– Metastatic RCC

Investigational Compounds

subcutaneous nivolumab + rHuPH20*
– Advanced RCC

Approved Indications

OPDIVO*
– 1L Metastatic Melanoma
– 1L Gastric
– Adjuvant Melanoma
– Adjuvant Bladder
– Adjuvant Esophageal/ Gastroesophageal
– Mesothelioma
– Previously treated advanced RCC
– Previously treated Gastric cancer (Japan, China)
– Previously treated Metastatic Head & Neck
– Previously treated Metastatic Melanoma
– Previously treated Metastatic MSI-High CRC
– Previously treated Metastatic Non-squamous NSCLC
– Previously treated Metastatic Squamous NSCLC
– Previously treated Metastatic Urothelial
– Previously treated Esophageal

OPDIVO* **+ *YERVOY****
– 1L Metastatic Melanoma
– 1L Mesothelioma
– 1L NSCLC
– 1L RCC
– Previously treated Metastatic MSI-High CRC
– Previously treated HCC

OPDIVO* **+ cabozantinib***
– Metastatic RCC

YERVOY*
– Adjuvant Melanoma
– Metastatic Melanoma

ABRAXANE
– Breast
– Gastric
– Locally Advanced or Metastatic NSCLC
– Metastatic Breast Cancer
– NSCLC
– Pancreatic
– Unresectable Pancreatic

Listed in this section are our clinical studies and approved indications for our marketed products in the related therapeutic area as of February 4, 2022. Whether any of the listed compounds ultimately becomes a marketed product depends on the results of clinical studies, the competitive landscape of the potential product's market, reimbursement decisions by payers and the manufacturing processes necessary to produce the potential product on a commercial scale, among other factors. There can be no assurance that we will seek regulatory approval of any of these compounds or that, if such approval is sought, it will be obtained. There is also no assurance that a compound which gets approved will be commercially successful. At this stage of development, we cannot determine all intellectual property issues or all the patent protection that may, or may not, be available for these investigational compounds.

Development portfolio by therapeutic area

Hematology

Phase I

Additional Indications

OPDIVO*
– Hematologic Malignancies

***BREYANZI* (liso-cel)**
– 3L+ Mantle Cell Lymphoma

ABECMA (ide-cel)
– High-risk Newly-Diagnosed Multiple Myeloma

Investigational Compounds

relatlimab*^
– Hematologic Malignancies

BET Inhibitor (CC-95775)
– Non-Hodgkin Lymphoma

BET Inhibitor (CC-90010)
– Hematologic Malignancies

BCMA ADC
– Relapsed/Refractory Multiple Myeloma

BCMA TCE
– Relapsed/Refractory Multiple Myeloma

BCMA NEX T
– Relapsed/Refractory Multiple Myeloma

GPRC5D CAR T
– Relapsed/Refractory Multiple Myeloma

GSPT1 CELMoD (CC-90009)
– Relapsed/Refractory Acute Myeloid Leukemia

Anti-SIRPα
– Non-Hodgkin Lymphoma

LSD1 Inhibitor
– Relapsed/Refractory Non-Hodgkin Lymphoma

CD19 NEX T
– Relapsed/Refractory Non-Hodgkin Lymphoma

iberdomide
– Non-Hodgkin Lymphoma

CD33 NKE
– Relapsed/Refractory Multiple Myeloma

CD47xCD20
– Non-Hodgkin Lymphoma

CK1α CELMoD
– Hematologic Malignancies

ROR1 CAR T
– Hematologic Malignancies

BCMA NKE
– Relapsed/Refractory Multiple Myeloma

Phase II

Additional Indications

OPDIVO*
– Non-Hodgkin Lymphoma (Diffuse Large B-cell Lymphoma)
– Non-Hodgkin Lymphoma (Follicular Lymphoma)
– Pediatric Hodgkin Lymphoma
– Primary Testicular Lymphoma

OPDIVO** + EMPLICITI*
– Relapsed/Refractory Multiple Myeloma

REBLOZYL*
– Non-Transfusion-Dependent Beta-Thalassemia

ONUREG
– Post HMA Failure MDS

BREYANZI
– 2L Diffuse Large B-cell Lymphoma Transplant non-Eligible
– 3L+Chronic Lymphocytic Leukemia
– 3L+ Follicular Lymphoma / Marginal Zone Lymphoma
– 2L+ Pediatric B-Cell Acute Lymphoblastic Leukemia
– 2L+ Primary CNS Lymphoma
– 1L High Grade B-cell Lymphoma

ABECMA* (ide-cel)
– High-risk Newly-Diagnosed Multiple Myeloma
– 2L Relapsed/Refractory Multiple Myeloma
– 4L+ Relapsed/Refractory Multiple Myeloma

Investigational Compounds

iberdomide
– Relapsed/Refractory Multiple Myeloma

A/I CELMoD (CC-92480)
– Relapsed/Refractory Multiple Myeloma

BET Inhibitor (BMS-986158)
– Hematologic Malignancies

Phase III

Additional Indications

OPDIVO*
– Refractory Hodgkin Lymphoma

EMPLICITI** + REVLIMID
– 1L Multiple Myeloma

REBLOZYL*
– ESA Naïve MDS
– MF Anemia

INREBIC
– MF Previously treated with Ruxolitinib

ONUREG
– Angioimmunoblastic T-cell Lymphoma
– Lower Risk MDS

ABECMA* (ide-cel)
– 3L Relapsed/Refractory Multiple Myeloma

BREYANZI
– 2L Diffuse Large B-cell Lymphoma Transplant Eligible

Approved Indications

REVLIMID
– 1L Multiple Myeloma
– Mantle Cell Lymphoma
– MDS
– Multiple Myeloma
– Previously treated Follicular Lymphoma
– Relapsed/Refractory Adult T-cell Leukemia/Lymphoma

OPDIVO*
– Advanced Hodgkin Lymphoma

POMALYST/IMNOVID
– Multiple Myeloma
– Relapsed/Refractory Multiple Myeloma
– AIDS related Kaposi Sarcoma
– HIV-negative Kaposi Sarcoma

EMPLICITI** + POMALYST/IMNOVID
– Relapsed/Refractory Multiple Myeloma

EMPLICITI** + REVLIMID
– Relapsed/Refractory Multiple Myeloma

SPRYCEL
– 1L CML
– Pediatric ALL
– Refractory CML

REBLOZYL*
– Transfusion-Dependent Beta-Thalassemia
– MDS Previously treated with ESA

INREBIC
– MF

ONUREG
– Post-Induction Acute Myeloid Leukemia Maintenance

BREYANZI
– 3L+ Diffuse Large B-cell Lymphoma

***ABECMA* (ide-cel)**
– 5L+ Relapsed/Refractory Multiple Myeloma



Immunology

Phase I

Investigational Compounds
TYK2 Inhibitor
– Autoimmune Disease
TLR 7/8 Inhibitor
– Autoimmune Disease
MK2 Inhibitor
– Autoimmune Disease
IL2-CD25
– Autoimmune Disease
Anti-CD40
– Autoimmune Disease
afimetoran
– Cutaneous Lupus Erythematosus

Phase II

Investigational Compounds
branebrutinib
– Rheumatoid Arthritis
– Sjögren's Disease
– Systemic Lupus Erythematosus
– Atopic Dermatitis
deucravacitinib
– Crohn's Disease
– Lupus Nephritis
– Systemic Lupus Erythematosus
– Ulcerative Colitis
– Discoid Lupus Erythematosus
iberdomide
– Systemic Lupus Erythematosus
cendakimab
– Atopic Dermatitis
afimetoran
– Systemic Lupus Erythematosus
S1PR1 Modulator
– Atopic Dermatitis
MK2 Inhibitor
– Ankylosing Spondylitis

Phase III

Additional Indications
ZEPOSIA
– Crohn's Disease

Investigational Compounds
deucravacitinib
– Psoriasis
– Psoriatic Arthritis
cendakimab
– Eosinophilic Esophagitis

Approved Indications

ORENCIA
– Active Polyarticular JIA
– Early Rheumatoid Arthritis
– JIA Intravenous
– JIA Subcutaneous
– Psoriatic Arthritis
– RA Auto injector
– RA Intravenous
– RA Subcutaneous
– Acute Graft versus Host Disease
ZEPOSIA
– Relapsing Multiple Sclerosis
– Ulcerative Colitis

Cardiovascular

Phase I

Investigational Compounds
Factor XIa Inhibitor^
– Thrombotic Disorders
Cardiac Myosin Inhibitor
– Hypertrophic Cardiomyopathy
ROMK Inhibitor
– Heart Failure

Phase II

Additional Indications
ELIQUIS^
– Pediatric Heart Disease

Investigational Compounds
mavacamten
– Non-obstructive Hypertrophic Cardiomyopathy
– Heart Failure with Preserved Ejection Fraction
danicamtiv
– Genetic Dilated Cardiomyopathy
milvexian^
– Thrombotic Disorders
FA-Relaxin
– Heart Failure

Phase III

Additional Indications
ELIQUIS^
– VTE prevention in pediatrics with ALL

Investigational Compounds
mavacamten
– Obstructive Hypertrophic Cardiomyopathy
– Obstructive Hypertrophic Cardiomyopathy Septal Reduction Therapy Eligible

Approved Indications

ELIQUIS[a]
– Stroke Prevention in Atrial Fibrillation
– Venous Thromboembolism Prevention Orthopedic Surgery
– Venous Thromboembolism Treatment

Fibrotic Diseases

Phase I

Investigational Compounds
NME 1
– Fibrosis

Phase II

Investigational Compounds
HSP47^
– Non-Alcoholic Steatohepatitis
LPA$_1$ Antagonist
– Pulmonary Fibrosis

Neuroscience

Phase I

Investigational Compounds
FAAH/MGLL Dual Inhibitor
– Neuroscience
Anti-Tau^
– Neuroscience
BTK Inhibitor
– Neuroscience
eIF2b Activator^
– Neuroscience

COVID-19

Phase II

Additional Indications
ORENCIA
– COVID-19 treatment

Investigational Compounds
SARS-CoV-2 mAb Duo^
– COVID-19 Therapy or Prevention#

Note: Above pipeline excludes clinical collaborations

[a] Development Partnership: ***OPDIVO, YERVOY*, Relatlimab:** Ono (our collaboration with Ono also includes other early stage compounds); ***EMPLICITI*:** AbbVie; **bempegaldesleukin:** Nektar; **cabozantinib:** Exelixis, Inc.; ***ELIQUIS:*** Pfizer; **Factor XIa Inhibitor:** Janssen Pharmaceuticals, Inc.; **HSP47:** Nitto Denko Corporation; **CD3xPSCA:** GeMoaB Monoclonals GmbH; ***ABECMA* (ide-cel):** 2seventy bio; ***REBLOZYL*:** Merck; **AHR:** Ikena Oncology; **CD22 ADC**: TriPhase Accelerator; **Immune Tolerance:** Anokion SA; **SARS-CoV-2 mAb Duo**: Rockefeller University; **TIGIT Bispecific**: Agenus; **farletuzumab-eribulin ADC**: Eisai; **rHuPH20**: Halozyme; **Anti-Tau**: Prothena Corporation PLC; **eIF2b Activator**: Evotec SE; **MAGE A4/8 TCE Bispecific**: Immatics.

^ Trial(s) exploring various combinations

Partner-run study